Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878736 | 0.84 | LMNA (0.43) | CHRM3ALDH1A1CHRM2CHRM1MEN1 | |
| SCHEMBL3216742 | 0.82 | CHRM3 (0.46) | CHRM3ALDH1A1KCNH2CHRM2CHRM1 | |
| SCHEMBL4619098 | 0.76 | ALPL (0.36) | ALDH1A1KCNH2ALPLPTBP1SSTR4 | |
| SCHEMBL4131231 | 0.75 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2APOLBALPL | |
| SCHEMBL4131229 | 0.75 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2APOLBALPL | |
| SCHEMBL4191418 | 0.74 | CHRM3 (0.51) | CHRM3ALDH1A1KCNH2CHRM2CHRM1 | |
| SCHEMBL3213540 | 0.74 | CHRM3 (0.46) | CHRM3ALDH1A1KCNH2CHRM2CHRM1 | |
| SCHEMBL4617611 | 0.73 | SSTR4 (0.42) | CHRM3KCNH2CHRM2CHRM1MEN1 | |
| SCHEMBL3210034 | 0.72 | CHRM2 (0.49) | CHRM3ALDH1A1KCNH2CHRM2CHRM1 | |
| SCHEMBL4190777 | 0.72 | LMNA (0.41) | CHRM3ALDH1A1KCNH2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | claimed |
| EP-1888525-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-02-20 | — | — | EP | claimed |
| WO-2006117754-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
| EP-1888525-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006117754-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885ALDH1A1 1047/4885KCNH2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.